Product
Flostream: A purpose-built microstent for angle-closure glaucoma
A minimally invasive implant designed specifically for the anatomy of Asian patients.
Product
A minimally invasive implant designed specifically for the anatomy of Asian patients.
The Challenge
In angle-closure glaucoma, the trabecular meshwork — the primary drainage site targeted by current minimally invasive devices — is physically blocked. This means existing MIGS solutions cannot be applied, leaving patients with limited surgical options and clinicians without a suitable minimally invasive tool.
When the angle is closed, the iris obstructs the view and physical path to the trabecular meshwork — the target of conventional MIGS — making accurate placement difficult.
Even if a device can be placed, the closed angle can obstruct the implant, blocking outflow and undermining long-term efficacy.
Downstream collector channels may no longer be functional in angle-closure disease, and devices that rely on the conventional outflow pathway may not restore drainage.
Anterior chamber implants carry a risk of corneal endothelial cell loss — a concern heightened in the more crowded anatomy of angle-closure patients.
Differentiation
Angle-closure glaucoma is most prevalent in Asian populations, where shallower anterior chambers make conventional MIGS devices unsuitable.
Flostream creates drainage independent of the trabecular meshwork, bypassing the blocked outflow pathway entirely. This anatomy-agnostic approach is intended to function in eyes where the angle is closed and conventional MIGS access is not possible.
A purpose-built, single-use deployer engineered for consistent, tactile-feedback-guided implant placement.
Pipeline & Milestones
Biocompatibility testing completed to ISO 10993. Bench testing and a non-human primate study with follow-up to 12 months completed, with supportive safety data.
HSA preparation and engagement with regulatory advisors.
Targeted first-in-human study in Singapore following successful preclinical completion.
Pivotal clinical trial to support regulatory approval and commercial launch.